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Decay-accelerating factor (DAF) is one of the complement regulatory proteins. Two isoforms of DAF have been identified in humans. In this
study, we isolated novel cDNAs encoding five isoforms of DAF from the human lung, which were generated by insertion of new exonic
sequences. RT-PCR revealed that all isoforms were expressed in almost all tissues tested, although the expression patterns and levels differed
among the tissues. Transfection of isoform vDAF1, 2, and 3 cDNAs into CHO cells showed that these molecules are soluble forms secreted after
glycosylation. Isoform vDAF4 and vDAF5 cDNAs included a part of and the entire intron 7 sequence, respectively, and the transfection of vDAF4
cDNA produced a large, glycosylated, membrane-bound form. These results suggest that more than seven isoforms of human DAF are involved in
the regulation of complement activation under physiological conditions through their specific structures and localization.
© 2006 Elsevier Inc. All rights reserved.Keywords: Decay-accelerating factor; CD55; Isoform; Alternative splicing; Gene structure; Complement; Host defenseDecay-accelerating factor (DAF, CD55) protects host cells
from inadvertent autolysis by complement [1], by accelerating the
decay of C3 and C5 convertases on host cell surfaces [2]. The
importance of DAF has been demonstrated by its increase in
tumor and inflammatory environments [3–5], through the
induction of inflammatory and tumor-associated factors [6,7],
suggesting that its expression is associated with the alteration of
cells under these pathological circumstances. Two isoforms of
DAF are known in humans, a glycosyl phosphatidylinositol
(GPI)-anchored form (gDAF) and a soluble form (sDAF) [8].
gDAF is the major form, which is composed of four N-terminal
complement control protein (CCP) domains, a heavily glycosy-
lated serine, threonine, and proline (STP)-rich domain, and a C-☆ Sequence data from this article have been deposited with the DDBJ/EMBL/
GenBank Data Libraries under Accession No. AB240566–AB240570 for the
cDNA sequences of DAF splicing variants vDAF1–5.
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doi:10.1016/j.ygeno.2006.01.006terminal GPI-anchored portion [9]. It is expressed on the plasma
membranes of all blood cells and almost all other cell types in
immediate contact with plasma component proteins. Unlike
gDAF, sDAF is present in bodily fluids and extracellular matrix
[8], and its levels are much lower than those of gDAF. It is
generated from the DAF gene by alternative usage of an optional
exon and lacks the GPI-anchored portion in the C-terminal [10].
Two types of DAF have been identified in mice, GPI-anchored
and transmembrane forms; they are alternative splicing products
and show distinct tissue distributions [11]. In the guinea pig,
alternative splicing of two optional exons generates three isoforms
of DAF, GPI-anchored, transmembrane, and soluble forms [12].
In addition, several isoforms with the modified STP-rich domain
have been documented in guinea pig DAF, which are also
generated by alternative splicing [13,14]. Thus, the expression of
DAF isoforms varies slightly among mammals, although the
major GPI-anchored form is common to all mammals.
The presence of multiple isoforms appears to be a common
feature of complement regulatory proteins of the regulators of
Fig. 1. Amplification of cDNA encoding the STP-rich domain of human DAF
by RT-PCR. RT-PCR was performed using cDNA isolated from the normal
regions of human tissues as templates and a primer set (F1 and R1). Lane 1,
lung; lane 2, colon; lane 3, peripheral blood; lane 4, liver; lane 5, stomach.
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cofactor protein (MCP). Multiple MCP isoforms have been
reported in mammals, including humans, murines, and guinea
pigs [15–19]. The MCP gene encodes a product structurally and
functionally similar to DAF [12]. However, there is little
information on the mechanism through which individual
isoforms contribute to complement regulation and how their
expression is related to the pathology of diseases such as cancer.
To understand the dynamism of DAF expression in human
tissues, we cloned cDNAs encoding the new DAF isoforms and
assessed the relationship between the DAF gene and its
expression in several tissues and characterized the structural
properties using recombinants. Since 1987, no new isoform has
been isolated in humans other than the already documentedFig. 2. (A) The new sequences inserted into DAF isoform vDAF1–3 cDNAs. The exo
amino acid sequences are also shown. Asterisks denote in-frame stop codons. (B) S
distinguished by a different pattern, which also corresponds to the exon with the sa
structure of the human DAF gene. By identification of three new exons (exons 11 thr
boxes represent exons of the DAF gene, in which exons 1 to 6, exons 7 to 9, and exo
region, respectively. The vDAF1–3 cDNA sequences are also depicted by the boxes c
codons in the cDNAs.gDAF and sDAF. We also discuss the sharing of roles by DAF
isoforms.
Results
Identification of novel isoforms of human DAF
RT-PCR to amplify cDNA encoding the STP-rich domain of
human DAF revealed a major band and several minor bands
with higher sizes (Fig. 1). These PCR products were observed in
almost all tissues tested, although the levels varied. Total DAF
expression, including the major and multiple minor forms, was
higher in the lung, peripheral blood, and liver than in the colon
and stomach. The individual levels of the minor bands were
estimated at less than 5% of gDAF levels. By cloning and
sequencing these cDNA bands, we confirmed that the main
band was derived from gDAF cDNA, and the minor bands were
cDNAs encoding six distinct isoforms of DAF. One of the six
isoforms was already reported as sDAF [3]. By alignment of the
newly identified sequences with the gDAF cDNA, we found
that three of the five variants, termed vDAF1, vDAF2, and
vDAF3, each included a new unique sequence, which was
inserted into the known sequence of gDAF cDNA (Figs. 2A and
2B). Through a homology search of these new sequences using
the DAF genome sequence, they were found to originate from
three new exons, which are located between exon 10 and former
exon 11 of the DAF gene (Fig. 2C). All splicing acceptor andnic nucleotide sequences identified in this study are underlined and the translated
chematic representation of the domain structures of vDAF1–3. Each domain is
me pattern. (C) Relationship between the vDAF1–3 cDNAs and the genomic
ough 13), the exon numbers were reassigned to total 14 exons in this study. The
ns 10 to 14 encode four CCP modules, an STP-rich domain, and the C-terminal
orresponding to the exons. The arrowheads below the boxes denote in-frame stop
Fig. 3. (A) The intron 7 sequence inserted into the vDAF4 and vDAF5 cDNAs. The new intron sequence used in the vDAF4 cDNA is underlined. The conserved
splicing donor and acceptor sites are in boldface. The highly conserved amino acid sequence PTXQK/RXT in exon 7 and intron 7 is also underlined. (B) The domain
structures of vDAF4 and vDAF5 in comparison with gDAF. Each domain is depicted with a different pattern, which corresponds to exons with the same pattern. (C)
Alternative splicing to generate vDAF4 and vDAF5 cDNAs. The solid lines and broken lines connecting two exons among exons 7 to 14 indicate splicing to produce
vDAF4 and vDAF5, respectively.
Fig. 4. Expression of sDAF and vDAF1–5 isoforms in the human tissues. RT-
PCR was performed to estimate levels of DAF isoforms sDAF and vDAF1–5 in
human tissues, using tissue cDNAs as templates and isoform-specific primer sets
(common forward primer and specific reverse primer). The PCR products with
the expected sizes were observed for all isoforms in almost all tissues tested.
Lane 1, lung; lane 2, colon; lane 3, peripheral blood; lane 4, liver; lane 5,
stomach.
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numbered the new exons as exons 11, 12, and 13 and
renumbered the last exon (previously known as exon 11) as
exon 14. vDAF1 cDNA included the sequence derived from
exon 11, which was preceded by exon 9 and followed by exon
14. The cDNA contained an in-frame stop codon in exon 14, in
which the reading frame was different from that in gDAF, but
similar to that in sDAF (Fig. 2A). Therefore, the sequence
stretch composed of exons 11 and 14 in vDAF1 cDNA encoded
77 amino acids similar to those of sDAF (Fig. 2B). It was also
found that the nucleotide sequence of exon 11 was a member of
the Alu family through a homology search with the database,
which was similar to exon 10, an optional exon for sDAF.
vDAF2 and vDAF3 cDNAs included new sequences derived
from exons 12 and 13, respectively, which encode unique 4- and
24-amino-acid sequences, respectively. Thus, vDAF1, vDAF2,
and vDAF3 lack the GPI-anchored portion in the C-termini, like
sDAF (Fig. 2B). Hydropathy analysis of the amino acid
sequences of vDAF1–3 confirmed that their C-termini were
rather hydrophilic. A homology search for the new 24 amino
acids in vDAF3 showed no significant similarity in the
database. The remaining two isoforms, termed vDAF4 and
vDAF5, included a part of and the full sequence of the intron 7
(Fig. 3A). The nucleotide sequence of intron 7 had no in-frame
stop codon in the nucleotide sequence and encoded 144 and 170
STP-rich amino acids in vDAF4 and vDAF5, respectively. The
insertion of intron 7 resulted in much longer STP-rich domains
in vDAF4 and vDAF5, since exons 7 to 9 encode a stretch of
STP-rich domain in gDAF (Figs. 3B and 3C). Interestingly,
exon 7 and intron 7 encoded tandem repeats of 33 amino acids,
each of which included a highly conserved core sequence
PTXQK/RXT, probably serving as an O-linked glycosylation
site.DAF isoforms are expressed in almost all tissues
RT-PCR specific for each isoform cDNA confirmed that the
DAF isoforms were expressed in almost all tissues tested.
Among the tissues, the lung, liver, and peripheral blood showed
relatively higher expression of all isoforms compared to those in
the digestive organs such as colon and stomach (Fig. 4). Very
low quantities of all DAF isoforms were expressed in the
stomach. Interestingly, the expression patterns of the DAF
isoforms were slightly different among the tissues. The
expression of vDAF1 to 3 was much lower than that of sDAF
and vDAF4/5 in the liver. This pattern was different from those
in other tissues such as the lung and peripheral blood, where
significant levels of vDAF1–3 were expressed, indicating the
tissue-specific expression of DAF isoforms.
Fig. 5. Characterization of recombinant DAF isoforms. (A) Western blot of recombinant vDAF1–3 in the CHO cell lysates. In control experiments, gDAF cDNA
construct and the vector without the insert DNA (V) were transfected into CHO cells. The arrowheads indicate the major product in each transformant. (B)Western blot
of recombinant vDAF1–3 and gDAF in the culture media. (C) Western blots of the recombinant vDAF1–3 treated with neuraminidase (N) or neuraminidase plus O-
glycanase (O). Culture media from vDAF1–3 transformants were treated with or without (−) enzymes. (D) Western blots of recombinant vDAF4 in CHO cell lysates.
Cell lysates of vDAF4 and gDAF as a control were treated with neuraminidase (N) or neuraminidase plus O-glycanase (O) or without enzymes (−).
Fig. 6. Quantification of the soluble forms of DAF in the culture medium by
ELISA. Data represent the mean levels of quadruple determinations and are
expressed as absorbance at 405 nm. The culture media used in this ELISAwere
prepared from the transient transformants, of which the same number of CHO
cells was plated.
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Chinese hamster ovary (CHO) cells
Transfection of vDAF1, vDAF2, and vDAF3 cDNA
constructs into CHO cells generated 44-, 38-, and 40-kDa
proteins, respectively, in the cell lysates (Fig. 5A) and 64-, 62-,
and 63-kDa proteins, respectively, in the culture media (Fig.
5B). The sizes observed in the cell lysates were somewhat
consistent with the molecular masses calculated from the amino
acid sequences, 44.9 kDa for vDAF1, 36.2 kDa for vDAF2, and
38.3 kDa for vDAF3. The molecular masses in the culture
media were about 20–25 kDa larger than those in the cell
lysates. In a control experiment, the transfection of the gDAF
cDNA construct produced a major band of about 70 kDa in both
cell lysate and culture medium (Figs. 5A and 5B). Treatment of
vDAF1 to 3 in culture media with neuraminidase and O-
glycanase resulted in a reduction of molecular masses to
approximately 55 and 40 kDa, respectively (Fig. 5C). These
results suggest that, unlike gDAF, vDAF1 to 3 are soluble forms
that are secreted out of cells after glycosylation.
The expression of vDAF4 in CHO cells revealed a protein
band with a large molecular size of 150 kDa in the cell lysate
(Fig. 5D). No detectable band was observed in the culture
medium from vDAF4 transformants. Treatment of cell lysate of
vDAF4 transformants with neuraminidase and O-glycanaseresulted in a reduction of the molecular mass to 110 and 70 kDa,
respectively. The molecular mass of vDAF4 peptide was
calculated to be 58.9 kDa based on the amino acid sequence.
These results suggest that vDAF4 is a membrane-bound DAF,
320 F. Osuka et al. / Genomics 88 (2006) 316–322probably bound through the GPI-anchored portion, and heavily
glycosylated by O-linked sugars.
The secretion of vDAF1–3 was confirmed by ELISA (Fig. 6).
High quantities of soluble DAF proteins were observed in the
culturemedia of vDAF1–3 transformants. In contrast, low levels of
DAF protein were observed in the culture medium of vDAF4
transformants, as well as in that of gDAF transformants, suggesting
its localization on the cells. In addition, using immunostaining with
anti-DAF antibody and FITC-labeled anti-rabbit IgG, we
observed vDAF1–3 proteins in the cytoplasm of CHO cells
and vDAF4 protein on the surface of the cells (data not shown).
Discussion
Two documented isoforms of human DAF, gDAF and sDAF,
are generated from the same gene by alternative splicing [8,10].
The sDAF cDNA sequence includes a unique exon, exon 10,
which is absent in gDAF cDNA. Insertion of exon 10 into the
cDNA causes a frameshift in translation of the following exon
14, which results in a unique N-terminal sequence of sDAF
lacking the GPI-anchored portion, and therefore sDAF is
secreted out of the cells. This situation is closely similar for
vDAF1 identified in this study. sDAF was reported to be present
in various bodily fluids such as tears, urine, and blood plasma
[8]. At present, however, we have no available method for
distinguishing these isoforms in bodily fluids, since they are
closely similar to each other in structure. Further study requires
specific antibodies against the individual forms. Using RT-PCR
in the present study, we observed that the soluble isoforms of
DAF, including vDAF1–3 and sDAF, were expressed in the
various tissues tested, suggesting that they are ubiquitously
expressed and secreted into bodily fluids. It was noteworthy that
the expression pattern of the DAF isoforms was slightly
different among the tissues. This result suggests that the splicing
of the DAF transcript was differently regulated in each tissue.
In our preliminary study with tissue specimens obtained from
patients with non-small-cell lung cancers (NSCLC), we noted
reduced levels of soluble forms of DAF in the tumor lesions,
compared with the normal regions of the same specimen (data
not shown). Low levels of the major gDAFwere also observed in
NSCLC at both the protein and the mRNA level (manuscript in
preparation). This down-regulation of DAF is unique for
NSCLC, since up-regulation has been reported in other tumors
such as colorectal cancer [4,20]. Further study is needed to
elucidate the mechanism for the down-regulation of DAF and its
biological significance in NSCLC.
From the analysis of the DAF gene, Nonaka et al. reported
that the sequence of intron 7 has no in-frame stop codon for the
gDAF cDNA and the translated amino acid sequence is rich in
serine, threonine, and proline, which is similar to the STP-rich
domain [13]. However, the transcript including the sequence of
intron 7 has yet to be isolated. Using isoform-specific RT-PCR,
we confirmed that, like vDAF1–3 mRNAs, vDAF4 and vDAF5
mRNAs were also expressed in almost all tissues, suggesting
that they are constitutively and ubiquitously expressed. It was
reported that the length of the STP-rich domain of DAF affects
the functional activity and that a longer STP-rich sequenceexhibits a higher inhibitory activity of complement activation
[14]. It was also reported that the O-linked carbohydrates of
DAF are not essential but are required for the full activity of this
molecule [21]. These results suggest that vDAF4 and vDAF5
may be powerful molecules executing higher activities to
defend the host cells from autologous complement attack.
Interestingly, it was reported that GPI-anchored DAF is a more
potent inhibitor of complement activation on the cell surface
than the soluble form of DAF and, inversely, that the soluble
form is a more efficient inhibitor in the fluid phase [22]. This
suggests that the DAF isoforms share their roles based on their
location, in that vDAF1–3, as well as sDAF, function more
efficiently in the fluid phase and vDAF4 and 5, as well as
gDAF, more potently on the surface of the host cells.
In conclusion, we isolated cDNAs encoding five new
isoforms of human DAF. Three of these new isoforms,
vDAF1–3, were soluble forms secreted after glycosylation,
and two, vDAF4 and 5, had long STP-rich domains and were
located on the cells. All new isoforms were ubiquitously
expressed in the tissues tested. These results suggest that
multiple isoforms of DAF are present in human tissues and share
their roles based on their specific structures and localization.Materials and methods
Isolation of mRNA from human tissues and cDNA synthesis
Tissue specimens were obtained from patients with lung, colorectal, hepatic,
and stomach cancers at the Fukushima Medical University Hospital. Normal,
nontumor tissues were obtained from regions sufficiently far away from the
cancerous lesions in these specimens. Peripheral leukocytes were obtained from
a volunteer. The mRNA was isolated from tissues using Isogen (Nippon Gene
Co., Ltd., Tokyo Japan) and converted to cDNA using a reverse transcriptase
Superscript III (Invitrogen, Carlsbad, CA, USA).
A signed consent form was obtained from each subject.
PCR-based cloning of DAF isoforms
To amplify cDNA fragments encoding the STP-rich domain of human DAF,
we performed RT-PCR using the lung cDNA as the template and the primers 5′-
GGATTCCATGATTGGAGAGCACTC-3′ (F1) and 5′-AAGTCAGCAAGCC-
CATGGTTACTAGC-3′ (R1). The resulting PCR products were cloned into the
pGEM-T Easy vector (Clontech, Palo Alto, CA, USA) and the nucleotide
sequences were determined using the dideoxy chain termination method using a
LI-COR DNA sequencer (Model 4000). To exclude PCR errors in the
sequences, more than six clones were determined for each sequence. The 5′-
and 3′-rapid amplification of cDNA ends was carried out to determine the 5′ and
3′ sequences of the cDNA, respectively, using a kit (Marathon; Clontech). The
full-length cDNA, temporarily termed vDAF1 to 5, was constructed by
overlapping these PCR products.
RT-PCR to amplify specific isoforms in tissues
We performed RT-PCR to amplify cDNA fragments for the individual DAF
isoforms using cDNAs from human tissues as templates and primer F1 and
isoform-specific reverse primers 5′-AGGAGTTCGAGACTGCAGTGAGC-
TACGATCACAC-3′ for sDAF, 5′-AGACCATCCTGGATAACACGGTGAA-
ACACCGTCT-3′ for vDAF1, 5′-TTCCTGGGATGCAAGGTTGGCTCAAC-
ATATCCAAA-3′ for vDAF2, 5′-GAAAATCTAAATCATCCCACAT-3′ for
vDAF3, and 5′-TGGGTTTCTGAAGAGTTGGTAGGGTTCCTGTAGC-3′
for vDAF4 and vDAF5. PCR products were observed by staining with
ethidium bromide on agarose gel after electrophoresis.
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To characterize the DAF isoforms, their recombinant proteins were prepared
using CHO cells. Briefly, the full-length cDNAwas subcloned into the pcDNA3
plasmid (Invitrogen), and 1 μg of the pcDNA3 construct was introduced into
about 80% confluent CHO cells using the Effectene transfection reagent
(Qiagen, Hilden, Germany) in a six-well microplate. CHO cells were maintained
in Dulbecco's modified essential medium supplemented with 10% fetal calf
serum. After 48 h of transfection, the CHO cells and culture medium were
recovered. The expression of DAF isoforms was confirmed by Western blots
using the cell lysates and culture medium as described below. For preparation of
stable expression clones, CHO cells were screened in the presence of neomycin
(G-418; Life Technologies, Inc., Grand Island, NY, USA) for more than three
passages.
Western blotting for DAF
CHO cells were washed once with phosphate-buffered saline (PBS) and
solubilized with an equal volume of 2× sodium dodecyl sulfate–polyacryl-
amide gel electrophoresis (SDS–PAGE) sample buffer (0.1 M Tris–HCl, pH
6.8, containing 4% SDS and 20% glycerol). After centrifugation of the
culture medium, the supernatant was mixed with an equal volume of 2×
SDS–PAGE sample buffer. The CHO cell lysate and culture supernatants
were subjected to SDS–PAGE on 7.5–8.0% polyacrylamide gel under
nonreducing conditions. After SDS–PAGE, the gels were transferred to
PVDF membranes (Bio-Rad Laboratories, Hercules, CA, USA). To inactivate
endogenous peroxidase, membrane filters were incubated in methanol
containing 0.3% hydrogen peroxide for 20 min at room temperature. To
block the activity of endogenous biotin, the membrane filters were incubated
in a biotin-blocking reagent (Dako, Glostrup, Denmark) for 10 min at room
temperature. The membrane filters were further incubated in Block Ace
(Dainippon Pharmaceutical Co., Tokyo, Japan) for 60 min at room
temperature, prior to incubation in PBS-T (PBS containing 0.01% Tween
20) containing 1% normal rabbit serum for 20 min at room temperature.
Subsequently, the membrane filters were incubated with a 1:500 dilution of
monoclonal anti-human DAF antibody (4F11) in PBS-T for 90 min at room
temperature. After being washed, the membrane filters were further incubated
with a 1:1000 dilution of biotinylated anti-mouse IgG antibody in PBS-T for
60 min. Color was developed with a Vectastain ABC kit (Vector Laboratories,
Burlingame, CA, USA) and NTB (Wako Pure Chemical Industries, Osaka,
Japan).
ELISA to quantify DAF in CHO culture medium
In this assay, 96-well microtiter plates were coated with anti-DAF
monoclonal antibody (4F11), followed by blocking with 0.25 M sodium
phosphate, pH 7.5, containing 0.1% BSA and 0.01% thimerothal (blocking
buffer). Twice-diluted culture supernatants (200 μl) were incubated in the
microtiter plate for 2 h at room temperature. After being washed twice with
0.25 M sodium phosphate, pH 7.5, containing 0.1% BSA (washing buffer);
the plates were incubated with 200 μl of 1000-fold-diluted biotin-conjugated
anti-DAF monoclonal antibody (1C6) for 2 h at room temperature. Biotin-
conjugated 1C6 was prepared using succinimidyl-6-(biotinamido) hexanoate
(Pierce, Rockford, IL, USA) as a linker. The plates were further incubated
with horseradish peroxidase-conjugated avidin (Dako) and the color was
developed using ABTS (Zymed, San Francisco, CA, USA) and H2O2.
Absorbance was assessed at 405 nm in a microplate reader. The culture
supernatant used in this ELISA was prepared from the transient transformants,
in which the number of CHO cells plated was adjusted to 5 × 10−5 cells per
well of a 6-well microplate.
Treatment with neuraminidase and endo-α-N-acetylgalactosaminidase
Selective removal of the terminal sialic acid and the O-linked glycans on
DAF was achieved by treatment of the recombinant DAF isoform with 50 μl
neuraminidase (Wako) alone and neuraminidase plus 4 μl of endo-α-N-
acetylgalactosaminidase (O-glycanase; Wako), in 200 μl of 10 mM sodiumphosphate buffer, pH 5.0, containing 0.15 M NaCl at 37°C for 16 h. The mixture
was supplemented with SDS–PAGE sample buffer and subjected to Western
blotting as described above.
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